TIAB SA-5069

Lub npe tshuaj:

N-(2-((2,3-difluorobenzyl)thio)-6-((((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide

SMILES Code:

O=S(N1CCC1)(NC2=NC(SCC3=CC=CC(F)=C3F)=NC(O[C@H](C)[C@@H](O)CO)=C2)=O

InChi Code:

InChI = 1S/C18H22F2N4O5S2/c1-11(14(26)9-25)29-16-8-15(23-31(27,28)24-6-3-7-24)21-18(22- 16) 30—1 0-12-4-2-5-13(19)17(12)20/h2,4-5,8,11,14,25-26H,3,6-7,9-10H2,1H3,(H ,21,22,23)/t11-,14+/m1/s1

InChi Key:

QZECRCLSIGFCIO-RISCZKNCSA-N

Lo lus tseem ceeb:

AZD-5069, AZD 5069, AZD 5069, 878385-84-3

Solubility:Soluble hauv DMSO

Cia:0 - 4 ° C rau lub sijhawm luv (hnub mus rau lub lis piam), lossis -20 ° C rau lub sijhawm ntev (hli).

Nqe lus piav qhia:

AZD-5069 yog ib tug muaj zog thiab xaiv CXCR2 antagonist nrog lub peev xwm los inhibit neutrophil tsiv teb tsaws rau hauv cov hlab cua hauv cov neeg mob COPD. AZD-5069 tau pom tias inhibit kev khi ntawm radiolabeled CXCL8 rau tib neeg CXCR2 nrog pIC50 tus nqi ntawm 9.1. Tsis tas li ntawd, AZD5069 inhibited neutrophil chemotaxis, nrog pA2 ntawm kwv yees li 9.6, thiab adhesion molecule qhia, nrog pA2 ntawm 6.9, teb rau CXCL1. AZD5069 yog ib qho maj mam thim rov qab antagonist ntawm CXCR2 nrog cov teebmeem ntawm lub sijhawm thiab qhov kub thiab txias tshwm sim ntawm cov tshuaj thiab kev sib khi kinetics. AZD-5069 kuj tseem muaj txiaj ntsig zoo rau cov neeg mob hauv cov mob inflammatory.

Hom phiaj: CXCR2